All eyes on Novo's new outlook on eve of 2021 report

On Wednesday morning, when Novo Nordisk presents its full-year financial results prior to the stock exchange opening, the attention of analysts and investors will be on the outlook for the new year, as growth isn’t expected to match 2021 levels due to production issues with obesity drug Wegovy.

Photo: Stine Tidsvilde

All eyes will be fixed on Novo Nordisk’s 2022 guidance when the company publicizes its full-year report on Wednesday morning.

Just as growth seemed to be on the highest gear shortly before Christmas, the Danish pharmaceutical company had to break the heavy news that it would not be able to meet the full demand for Wegovy in the US until the second half of 2022.

Already a subscriber? Log in.

Read the whole article

Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

Britt Meelby Jensen wants to rebuild trust in Ambu

After a turbulent time for Ambu under Juan Jose Gonzalez’s reign, new chief executive appointee Britt Meelby Jensen aims to rebuild the trust in the medtech firm, which has downgraded its expectations seven times over the past three years.

Outgoing Ambu CEO commends colleagues

”A true privilege,” says Juan Jose Gonzalez, describing his time as CEO at Ambu, which came to an end with Thursday’s announcement that Britt Meelby Jensen would take over the role.

Further reading

Related articles

Latest news

See all jobs